Christophe Queva net worth and biography

Christophe Queva Biography and Net Worth

Christophe Quéva, PhD, is Chief Scientific Officer and Senior Vice President, Research. Christophe is responsible for directing and advancing the company’s development program based on its next-generation immunotherapy platform of oncolytic viruses. An industry veteran, Christophe has nearly two decades’ immuno-oncology experience and successful portfolio-building track record from target identification and development through regulatory approval.

Prior to joining Oncorus, Christophe was Chief Scientific Officer at iTeos Therapeutics where his responsibilities included leading the generation of an innovative immuno-oncology portfolio of small molecule and antibody programs and overseeing the company’s translational medicine strategy for its A2A antagonist and TIGIT programs. Before iTeos, he held successive senior positions at AstraZeneca, Amgen and Gilead Sciences where he led or supported drug discovery programs for oncology and inflammatory diseases, from target selection to commercial approval for small molecules and biologics.

A holder of five patents and widely published, Christophe trained as a post-doctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle after receiving his PhD in Life and Health Sciences from the University of Lille, France.

What is Christophe Queva's net worth?: The estimated net worth of Christophe Queva is at least $4,588.92 as of April 30th, 2021. Dr. Queva owns 36,420 shares of Oncorus stock worth more than $4,589 as of April 24th. This net worth evaluation does not reflect any other assets that Dr. Queva may own. Learn More about Christophe Queva's net worth.
How do I contact Christophe Queva?: The corporate mailing address for Dr. Queva and other Oncorus executives is , , . Oncorus can also be reached via phone at 339-240-3330 and via email at [email protected]. Learn More on Christophe Queva's contact information.
Has Christophe Queva been buying or selling shares of Oncorus?: Christophe Queva has not been actively trading shares of Oncorus over the course of the past ninety days. Most recently, Christophe Queva sold 23,555 shares of the business's stock in a transaction on Friday, April 30th. The shares were sold at an average price of $15.97, for a transaction totalling $376,173.35. Following the completion of the sale, the senior vice president now directly owns 36,420 shares of the company's stock, valued at $581,627.40. Learn More on Christophe Queva's trading history.
Who are Oncorus' active insiders?: Oncorus' insider roster includes Stephen Harbin (COO), and Christophe Queva (SVP). Learn More on Oncorus' active insiders.

Christophe Queva Insider Trading History at Oncorus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/30/2021	Sell	23,555	$15.97	$376,173.35	36,420
4/28/2021	Sell	17,990	$15.22	$273,807.80	77,376
4/26/2021	Sell	54	$15.00	$810.00	77,376
4/6/2021	Sell	5,300	$15.01	$79,553.00	77,430

Christophe Queva Buying and Selling Activity at Oncorus

Oncorus Company Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $0.13

$0.13

$0.20

50 Day Range

MA: $0.07

$0.01

$0.13

2 Week Range

Now: $0.13

$0.01

$0.47

Volume

135,900 shs

Average Volume

1,333,593 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.6

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.